Robert Collins, MD
Hematology & Oncology · Dallas, TXNPI 1851350979
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $455 of the $585 with a category attached, or 77.9%. Servier Pharmaceuticals LLC accounts for 77.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $500 and has fallen 89.7% since, to $52 in 2024. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 4 payments — averaging $146.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$455
- Tempus AI, Inc$52
- Carter Bloodcare$45
- Takeda Pharmaceuticals U.S.A., Inc.$33
Across 25 payments — averaging $6405.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$76K
- AstraZeneca$30K
- Bristol Myers Squibb$22K
- Agios Pharmaceuticals, Inc.$11K
- National Marrow Donor Program$9K
- Boehringer Ingelheim International GmbH$7K
- plus $5K from 1 others
What the payments were for
- Speaking & faculty fees$45578%
- Food & beverage$9717%
- Education$336%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 1 | $455 |
| Tempus AI, Inc | 1 | $52 |
| Carter Bloodcare | 1 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIBSOVO$455
How this compares
$585 in reported general payments places this provider in the 25th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 46 | $665,557 |
| BosulifBosutinib | 33 | $613,932 |
| VenclextaVenetoclax | 44 | $367,672 |
| SprycelDasatinib | 14 | $133,264 |
| GleevecImatinib Mesylate | 13 | $107,770 |
| Imatinib Mesylate | 18 | $19,775 |
| Posaconazole | 14 | $16,678 |
| Acyclovir | 124 | $2,233 |
| Atovaquone | 11 | $1,859 |
| ValacyclovirValacyclovir Hcl | 13 | $1,248 |
| Allopurinol | 41 | $402 |
| Penicillin V Potassium | 13 | $305 |
| Montelukast Sodium | 12 | $124 |
| Pantoprazole Sodium | 12 | $93 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $74 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.